SERMs, Selective estrogen receptor

DVT, deep vein thrombosis HIT, heparin-induced thrombocytopenia PAI-I, plasminogen activator inhibitor PE, pulmonary embolism SERM, selective estrogen receptor modulator VTE, venous thromboembolism. 

GP glycoprotein SERM selective estrogen receptor modulator... 

SERM, selective estrogen receptor modulator SERD, selective estrogen receptor down regulator LHRH, luteinizing hormone-releasing hormone. 

Control of ovarian secretion and the actions of its hormones. In the follicular phase the ovary produces mainly estrogens in the luteal phase it produces estrogens and progesterone. SERMs, selective estrogen receptor modulators. See text. 

Vessieres A, Top S, Beck W, Hillard EA, Jaouen G (2006) Metal complex SERMs (Selective Estrogen Receptor Modulators). The influence of different metal units on breast cancer cell antiproliferative effects. Dalton Trans 4 529-541... 

There also exist a class of ligands referred to as SERMs (selective estrogen receptor modulators) that display tissue-selective pharmacology [13]. Raloxifene and tamoxifen are two clinically used SERMs for which structures are available. Crystal structures of the estrogen receptor bound to different ligands (estradiol, tamoxifen, or raloxifene) reveal that ligands of different sizes and shapes induce a spectrum of receptor conformational states. These states can be interpreted by the cellular complexion of co-regulators and the environment of the local promoter of... 

SERMs selective estrogen receptor modulators TMP trimethoprim... 

SERD selective estrogen receptor dowmegulator SERM selective estrogen receptor modulators TAC paclitaxel, doxorubicin, and cyclophosphamide (regimen) TNM tumor-node-metastasis staging system... 

Antiestrogen approaches for the therapy of hormone-receptor positive breast cancer include the use of selective estrogen-receptor modulators (SERMs), selective estrogen receptor downregulators (SERDs), and aromatase inhibitors (AIs). 

Chapter 2, by G. Jaouen et al, underlines the renewed interest in research on organometallic steroids and their ability to bind with specific receptors, where they can also act as inhibitors as, for example, in the case of the estrogen receptor. But this is a vast area, whether in terms of radiopharmaceuticals or the topic of SERMs (selective estrogen receptor modulators), for example, as demonstrated by the ferrocifens. This research may prove to be of social benefit in addressing the problems caused by endocrine disrupters, where the organometallic component is still evolving. 

Scheme 1.9 summarizes two approaches that are most developed to date, to illustrate the targeting principle. The SERMs (Selective Estrogen Receptor Modulators), of which tamoxifen 16 (active metabolite hydroxytamoxifen, OH-Tam, 17) is the prototype, represented a significant step forward in the treatment of hormone-dependent breast cancer (ER-t). To address the problem of nonhormone-dependent (ER-) tumors, hydroxyferrocifen (OH-ferrodfen, 18) was... 

Metal Complex SERMs (Selective Estrogen Receptor Modulators) 69... 

---